4-Hydroxytestosterone Breast Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for breast cancer, particularly estrogen receptor-negative (ER-negative) tumors, are ineffective due to limitations in aromatase inhibitors and hormonal treatments, with a need for alternative compounds that can target androgen receptors (AR) without aromatization, to inhibit tumor growth and metastasis.
Innovation Solution
The use of 4,17β-dihydroxyandrost-4-ene-3-one (4-hydroxytestosterone) and its esters, which specifically bind to the androgen receptor (AR) with high affinity, are not metabolized by aromatase or 5-alpha reductase, allowing for effective therapeutic and prophylactic treatment of breast cancer, including ER-negative cases, through topical administration to directly target cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If aromatase inhibitors are used to block estrogen production, then ER-positive breast cancer growth is inhibited, but ER-negative tumors remain untreated and aromatizable androgens may be converted to estrogens promoting cancer growth
Solution Approach 1:
The patent changes the chemical parameter of the steroid compound by introducing a 4-hydroxy group modification to testosterone, creating 4-hydroxytestosterone. This structural modification prevents aromatization while maintaining androgen receptor binding affinity, transforming the compound's metabolic fate and biological activity profile to achieve efficacy against both ER-positive and ER-negative breast cancers
Solution Approach 2:
The patent converts the harmful aromatization pathway (which produces estrogen that promotes cancer growth) into a beneficial outcome by designing a compound that cannot be aromatized. The blocked aromatization pathway prevents harmful estrogen production while the compound's androgenic activity promotes apoptosis in breast cancer cells, including ER-negative cells
2Ease of operation
If testosterone is administered to target androgen receptors, then AR-positive breast cancer cells are affected, but rapid metabolization to estradiol or DHT promotes cancer growth
Solution Approach 1:
The patent extracts or removes the problematic aromatizable A-ring structure from testosterone by introducing a 4-hydroxy group that blocks aromatization. This extraction of the harmful metabolic pathway allows the compound to maintain androgenic activity without generating harmful estrogen metabolites
Solution Approach 2:
The 4-hydroxytestosterone compound acts as an intermediary substance that delivers androgenic therapeutic effects without undergoing the harmful metabolic transformation to estradiol. It serves as a bridge between androgen therapy and cancer treatment, providing the desired biological effect while avoiding the harmful metabolic byproducts
3Reliability
If Tamoxifen is used as an estrogen receptor antagonist, then breast cancer growth is inhibited, but tachyphylaxy and estrogen-like side effects limit long-term use
Solution Approach 1:
Instead of using an estrogen receptor antagonist like Tamoxifen that blocks estrogen signaling, the patent inverts the approach by using an androgen receptor agonist (4-hydroxytestosterone) that activates AR signaling to induce apoptosis. This inverted mechanism avoids Tamoxifen's side effects and tachyphylaxy while achieving anti-proliferative effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds induce anabolic effects in AR-positive cells and apoptotic effects in breast cancer cells, providing a significant therapeutic advantage by effectively treating both ER-positive and ER-negative tumors, reducing tumor volume, and preventing recurrence with minimal systemic side effects.
Implementation Method 1
specifically bind to the androgen receptor (AR) with high affinity
Implementation Method 2
not metabolized by aromatase or 5-alpha reductase
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
The present invention relates to novel uses of a steroid compound, which specifically binds to the androgen receptor (AR) but which is not metabolized by aromatase to a process for their preparation, to pharmaceutical compositions containing them, and to the use of said compounds for the prophylaxis and/or treatment of hormone-dependent or hormone receptor regulated cancers in mammals.